Open AccessFrontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
Author(s) -
Alderuccio Juan Pablo,
Desai Amrita,
Yepes Monica M.,
Chapman Jennifer R.,
Vega Francisco,
Lossos Izidore S.
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1382
Subject(s) - brentuximab vedotin , medicine , anaplastic large cell lymphoma , breast implant , lymphoma , oncology , implant , hodgkin lymphoma , dermatology , surgery
Key Clinical Message We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.